News

Recent News

Advaxis, Inc. Completes $9.4 Million Equity Financing

Advaxis, Inc. Phase I/II Results of Lovaxin C in Cervical Cancer Study Released

Advaxis Completes Dosing and Enrollment of Third Cohort of Patients in Phase I/II Cervical Cancer Vaccine Trial

Two Leading Biotech Publications Report on Advaxis� Listeria Platform Technology

Recent HPV Findings by Centers for Disease Control and Prevention Validate Advaxis, Inc.'s Treatable Population

Home